The ELN-2022 prognostic stratification of AML classifies patients with NPM1wt/FLT3-ITD and concurrent adverse risk cytogenetics in the poor risk category, although this assumption is not based on solid data [4]. Here, FLT3 is linked to acute myeloid leukemia.